The issue is the Ukraine invasion in the short term, this is being seen across biotechs everywhere. For me it’s a signal to find some time and double down on research, because it looks like there will be an amazing 12-18 month buying window for multiple biotechs (I know I won’t actually have time to research ha) there is nothing as good as an incentivised founder. Absolutely nothing like it. I work 12-14 hours a day as a business owner and about 7 of those hours is work that an ‘employer’ would never know if it didn’t get done i innately know if I was an employee I wouldn’t be doing the extra work as a wage just couldn’t compensate for what is involved. There’s some data on founder / owner companies outperforming and that this is a factor which funds look for to predict outperformance ‘Ultimately Australia is one of the very best places to be for biotech - R&D grant, strong deep & resilient capital markets, and the new ‘patent box’ Australian commercialised patents developed here - 17%
